Výsledky vyhledávání - "S. Doyle-Lindrud"

A phase I trial of weekly paclitaxel, 13- cis -retinoic acid, and interferon alpha in patients with prostate cancer and other advanced malignancies

Autor: S. Doyle-Lindrud, Eric J. Rubin, Elizabeth Poplin, Susan Goodin, Terry Capanna, Stephanie Beers, Dmitri Dvorzhinski, Anu Thalasila, Robert S. DiPaola, J. Shih

Publikováno v: Cancer Chemotherapy and Pharmacology. 52:119-124

Based on prior studies demonstrating the effect of 13- cis-retinoic acid and interferon alpha (CRA/IFN) in decreasing the expression of the antiapoptotic protein bcl-2, our prior clinical study of CRA/IFN with paclitaxel (TAX) administered every 3 we

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f63044392a742419c55d28de8a8d59cb
https://doi.org/10.1007/s00280-003-0644-6

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Characterization of a Novel Prostate-Specific Antigen–Activated Peptide-Doxorubicin Conjugate in Patients With Prostate Cancer

Autor: S. Ebbinghaus, Adrienne Williams, Eric J. Rubin, Robert S. DiPaola, Greg Winchell, John J. Rinehart, Karen E Wickersham, Ned Adams, Susan Goodwin, Michelle Fontaine, John Nemunaitis, S. Doyle-Lindrud, Deutsch Paul J, Michael Schwartz, Marie Ciardella, Terry Capanna, Siu-Long Yao

Publikováno v: Journal of Clinical Oncology. 20:1874-1879

PURPOSE: To evaluate safety and pharmacokinetics (PK), and determine the recommended dose for efficacy studies, of L-377202, a novel peptide conjugate of doxorubicin (Dox) that releases the active metabolites leucine-doxorubicin (Leu-Dox) and Dox on

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::77ea8942821a6b85139f03969dc7c634
https://doi.org/10.1200/jco.2002.07.001

Zobrazit plný text záznamu

Effect of docetaxel in patients with hormone-dependent prostate-specific antigen progression after local therapy for prostate cancer

Autor: Weichung Joe Shih, Terry Capanna, Mary B. Todd, Patrick J. Medina, S. Doyle-Lindrud, Robert S. DiPaola, Jessica Winnie, Sybil Abraham, Susan Goodin

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 23(15)

Purpose To evaluate docetaxel in the treatment of patients with early-stage prostate cancer with prostate-specific antigen (PSA) progression after local therapy without androgen ablation therapy. Patients and Methods Twenty-five patients with adenoca

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::47b695612db2c211894489f33f15dabf
https://pubmed.ncbi.nlm.nih.gov/15738547

Zobrazit plný text záznamu

A phase II trial of docetaxel and vinorelbine in patients with hormone-refractory prostate cancer

Autor: Lixian Jin, Kamakshi V. Rao, Terry Capanna, Mary B. Todd, S. Doyle-Lindrud, Nisha Dave, Susan Goodin, Elizabeth Engle, Robert S. DiPaola, Michael P. Kane

Publikováno v: Cancer chemotherapy and pharmacology. 56(2)

Recent studies of docetaxel have demonstrated improved survival over mitoxantrone and prednisone in patients with hormone-refractory prostate cancer (HRPC), supporting the study of novel docetaxel-containing regimens as primary therapy or following i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::501bf3238a8d22677d3eacaa38dcc474
https://pubmed.ncbi.nlm.nih.gov/15838657

Zobrazit plný text záznamu

Warburg science goes to the bedside: A phase I trial of 2-deoxyglucose in patients with prostate cancer and advanced malignancies

Autor: Robert S. DiPaola, M. N. Stein, Weichung Joe Shih, Dmitri Dvorzhinski, S. Doyle-Lindrud, Eileen White, Susan Goodin, Stephanie Beers, Simantini Eddy, Eric H. Rubin

Publikováno v: Journal of Clinical Oncology. 26:16087-16087

16087 Background: A profound, but therapeutically unexploited, difference between cancer and normal tissues is the preferential utilization of glycolysis (the ‘Warburg effect‘) for energy by cancer cells. Additionally, similar to mechanisms of ch

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0843a41c2a4d8a4fe2c6726b0dd6fe7f
https://doi.org/10.1200/jco.2008.26.15_suppl.16087

Zobrazit plný text záznamu

A phase II trial of 13-cis retinoic acid, interferon, docetaxel, and estramustine (RITE) for the treatment of hormone refractory prostate cancer (HRPC)

Autor: Eric H. Rubin, Chandrika Jeyamohan, Eileen White, D. Metzger, Amit R. Mehta, M. N. Stein, S. Doyle-Lindrud, Susan Goodin, Robert S. DiPaola, Mary B. Todd

Publikováno v: Journal of Clinical Oncology. 25:15542-15542

15542 Background: Efficacy of chemotherapy for the treatment of HRPC is limited secondary to the development of multiple mechanisms of resistance. In our prior studies, we demonstrated the safety and activity of docetaxel (T) 40 mg/m2 given with 13-c

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0cecba60d22f10dc34e3c42f67d8ade0
https://doi.org/10.1200/jco.2007.25.18_suppl.15542

Zobrazit plný text záznamu

A phase II salvage trial of transdermal estradiol in the treatment of hormone and chemotherapy refractory prostate cancer: A Cancer Institute of New Jersey Oncology Group Study NJ1803

Autor: Robert S. DiPaola, Mary B. Todd, H. Durivage, R. Zager, A. Altscher, J. Shih, Susan Goodin, S. Doyle-Lindrud, E. Teller, N. Morganstein

Publikováno v: Journal of Clinical Oncology. 22:4695-4695

4695 Background: Options for patients with progression of prostate cancer following androgen ablation and chemotherapy are limited. Prior studies have demonstrated the efficacy of estrogen in this ...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::955fe89ee6bd09a58d1cbd46568a2ab2
https://doi.org/10.1200/jco.2004.22.90140.4695

Zobrazit plný text záznamu

A phase I/II trial of 13-cis retinoic acid, alpha interferon, docetaxel, and estramustine (R.I.T.E.) for the treatment of hormone refractory prostate cancer (HRPC)

Autor: E. Teller, A. Altscher, B. Hillard, Susan Goodin, S. Doyle-Lindrud, Robert S. DiPaola, Weichung Joe Shih, Y. A. Elsayed, Eric H. Rubin

Publikováno v: Journal of Clinical Oncology. 22:4707-4707

Advanced prostate cancer is only temporarily controlled with androgen ablation therapy. In order to overcome tumor resistance, we developed a epithelial cell line model to dissect out important mechanisms of resistance such as mutations in p53 and bc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::37acf1f0059c68806e380ed64d2e391a
https://doi.org/10.1200/jco.2004.22.90140.4707

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání